Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants
about
A discriminative analytical method for detection of CES1A1 and CES1A2/CES1A3 genetic variantsIndividualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics.The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humansThe effect of ethanol on oral cocaine pharmacokinetics reveals an unrecognized class of ethanol-mediated drug interactions.Oseltamivir treatment prevents the increased influenza virus disease severity and lethality occurring in chronic ethanol consuming miceSurge in expression of carboxylesterase 1 during the post-neonatal stage enables a rapid gain of the capacity to activate the anti-influenza prodrug oseltamivir.Transdermal and oral dl-methylphenidate-ethanol interactions in C57BL/6J mice: transesterification to ethylphenidate and elevation of d-methylphenidate concentrationsEffects of alcohol on human carboxylesterase drug metabolism.The role of human carboxylesterases in drug metabolism: have we overlooked their importance?Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalaprilInhibition of MAO-A and stimulation of behavioural activities in mice by the inactive prodrug form of the anti-influenza agent oseltamivirCES1P1 variant -816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril.Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers.The rationality for using prodrug approach in drug discovery programs for new xenobiotics: opportunities and challenges.Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review.Pharmacokinetic properties of anti-influenza neuraminidase inhibitors.Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance.Application of physiologically based pharmacokinetic modeling to predict drug disposition in pregnant populations.CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors.Efficient in vitro refolding and functional characterization of recombinant human liver carboxylesterase (CES1) expressed in E. coli.Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms.Effect of carboxylesterase 1 S75N on clopidogrel therapy among acute coronary syndrome patients.Carboxylesterase 1 (CES1) genetic polymorphisms and oseltamivir activation.Gly143Glu polymorphism of the human carboxylesterase1 gene in an Asian population.The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects.A Comprehensive Functional Assessment of Carboxylesterase 1 Nonsynonymous Polymorphisms.Clinical implications of genetic variation in carboxylesterase drug metabolism.Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans.Carboxylesterase 1 Polymorphism Impairs Oseltamivir Bioactivation in Humans
P2860
Q28257265-2BC2CE02-BCF8-45FA-A0FA-030F40E4FEB8Q30373969-CC8C2C1A-B43A-4F18-9BAA-EA6C48A383D0Q33596716-A20CBD58-D00C-4D64-B0AB-C17ECCA799AFQ33613348-CA1C60AC-2667-48B9-982A-D7AE55804903Q34020714-42689F89-99C3-43E2-AE7D-31CD86C9F8F5Q34743315-07F364B1-93F2-4F73-A925-08BE951068B2Q35600580-7267EE01-5C9C-4CFA-BEF5-5242C1241CAAQ35668517-91BF5372-16B8-427F-91BF-C244A98CA1CBQ36066647-F80E3CC1-183E-4574-A04E-5F880708930CQ36243667-A54AF393-5F0D-4859-8E42-B3EACCD230A8Q36783997-FBEF6D95-3F1C-4DCB-AF16-55CD3ED0E7F1Q36896568-CBC7045A-B06F-45AB-AF12-BD227C5C435AQ37702261-0D5232D4-1B73-4913-800F-986BB6A42548Q37853071-325E6EDC-81D6-42C9-984E-A94930535797Q38051213-FEE019E4-2F73-4C0E-90ED-DB5942A6EEBCQ38084212-8905F464-B084-4511-89A9-F25F9D825196Q38799423-333CC0DA-0D06-49DF-B37D-4651CCF4F8DAQ38802632-E847ADAB-DCB1-4409-92FB-0BA88A7A3235Q38863876-31D08379-28DA-4095-9E60-79A300D9DEA4Q38914678-01B89E24-E7F8-4681-B093-035DF2C58E22Q40734518-53F4FD25-E1ED-403C-AAB9-C39422229BC9Q41242987-4D50857B-05BA-4A4C-9D0D-949A0F2F76DFQ46155415-CF1AA9E1-9885-463A-B5BF-B89FD35B3639Q46468315-B4662B9D-720A-46ED-935C-4EA4BED117F6Q47827847-64AC3424-292C-42EE-8DCE-1BB56F09C0F8Q47909214-DDA64924-01C4-42BC-AE18-40805BCD7FD2Q49628042-9D465263-B4B5-45C1-B423-D254052F07CDQ53601038-B26D2CF0-F1ED-4229-A313-A1933E3C7D0FQ57825111-3AAE8FA7-4DBE-47C8-B1D1-5783A1722949
P2860
Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Activation of the antiviral pr ...... ed carboxylesterase 1 variants
@ast
Activation of the antiviral pr ...... ed carboxylesterase 1 variants
@en
Activation of the antiviral pr ...... ed carboxylesterase 1 variants
@nl
type
label
Activation of the antiviral pr ...... ed carboxylesterase 1 variants
@ast
Activation of the antiviral pr ...... ed carboxylesterase 1 variants
@en
Activation of the antiviral pr ...... ed carboxylesterase 1 variants
@nl
prefLabel
Activation of the antiviral pr ...... ed carboxylesterase 1 variants
@ast
Activation of the antiviral pr ...... ed carboxylesterase 1 variants
@en
Activation of the antiviral pr ...... ed carboxylesterase 1 variants
@nl
P356
P1476
Activation of the antiviral pr ...... ed carboxylesterase 1 variants
@en
P2093
Hao-Jie Zhu
John S Markowitz
P356
10.1124/DMD.108.024943
P407
P577
2009-02-01T00:00:00Z